Physicians recommend that patients with chronic obstructive pulmonary disease (COPD) quit smoking and use steroids, ...
But Verona is off to a strong start as Ohtuvayre generated sales of $42 million in 2024, the company reported on Tuesday.
Benralizumab is more effective than prednisolone in treating eosinophilic exacerbations in patients with asthma and COPD.
For patients with COPD, budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol.
Boobalan Pachaiyappan, an analyst from Roth MKM, has initiated a new Buy rating on Verona Pharma (VRNA).Stay Ahead of the Market:Discover ...
Chief executive David Zaccardelli said Ohtuvayre was off to an "exceptionally strong start," with more than 3,500 healthcare ...
Verona Pharma’s Ohtuvayre has a solid market entry, but its valuation is high. Read why VRNA stock remains a buy for ...
Hosted on MSN21h
AerWave Medical concludes study of ultrasound therapy for COPDThe study, involving five patients, demonstrated the procedural efficiency and feasibility of AerWave's technology.
1don MSN
Additional research addressing the connection between chronic obstructive pulmonary disease (COPD) and metabolic syndrome is ...
News Medical on MSN1d
Addressing COPD and metabolic syndrome requires comprehensive research effortsAdditional research addressing the connection between chronic obstructive pulmonary disease (COPD) and metabolic syndrome is ...
Approximately $36 million and $42 million net product sales of Ohtuvayre for the fourth quarter and full year 2024, respectivelyMore than 3,500 ...
a once-daily dry powder inhaler for treatment of COPD in routine clinical practice in a new-user, 1:1 propensity score-matched cohort study. The study included 20,388 propensity score-matched ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback